Caribou Biosciences (CRBU) Non-Current Deferred Tax Liability (2020 - 2025)

Caribou Biosciences (CRBU) has 6 years of Non-Current Deferred Tax Liability data on file, last reported at $4.3 million in Q4 2025.

• On a quarterly basis, Non-Current Deferred Tax Liability fell 47.23% year-over-year to $4.3 million in Q4 2025; TTM through Dec 2025 was $4.3 million, a 47.23% decrease from a year earlier, with the FY2025 full-year figure at $4.3 million, down 47.23% from the prior year.
• Non-Current Deferred Tax Liability for Q4 2025 stood at $4.3 million, up from $548000.0 in the prior quarter.
• Over the last five years, Non-Current Deferred Tax Liability for CRBU reached as high as $10.9 million in Q4 2022 and fell as low as $155000.0 in Q2 2021.
• Historically, Non-Current Deferred Tax Liability has averaged $1.8 million across 5 years, with a median of $548000.0 in 2025.
• Across the five-year window, Non-Current Deferred Tax Liability soared 2043.87% in 2021 and sank 94.88% in 2023, its largest moves.
• Year by year, Non-Current Deferred Tax Liability stood at $3.3 million in 2021, then surged by 227.54% to $10.9 million in 2022, then sank by 94.88% to $557000.0 in 2023, then surged by 1351.17% to $8.1 million in 2024, then tumbled by 47.23% to $4.3 million in 2025.
• Per Business Quant data, the three most recent Non-Current Deferred Tax Liability figures were $4.3 million in Q4 2025, $548000.0 in Q3 2025, and $548000.0 in Q2 2025.